There is a national crisis slowing clinical research due to staffing shortages, administrative burden and current clinical trial business models. If the crisis is not rapidly addressed, the field of oncology faces a significant threat to patient treatment access and novel drug development that can affect the clinical landscape for years to come.
SITC’s Call to Action and Summit Overview
Based on preliminary discussions with various stakeholders concerning the significance of the crisis, The Society for Immunotherapy of Cancer (SITC) hosted the Crisis in Clinical Research Virtual Summit on Wednesday, Aug. 17, from 10:00 a.m.–3:30 p.m. EDT. The summit was designed as a free, public event that featured expert panel discussions, invited speakers, and attendee question and answer periods. In all, the multi-stakeholder virtual summit convened over 600 attendees and 30 panelists demonstrating the critical need across the field for solutions pertaining to the crisis. Attendees included oncologists, administrators, the National Cancer Institute (NCI), the US Food and Drug Administration (FDA), pharmaceutical companies, contract research organizations (CRO) and other major oncology professional organizations.